BioCentury
ARTICLE | Clinical News

Teysuno tegafur/gimeracil/oteracil potassium regulatory update

August 19, 2013 7:00 AM UTC

Nordic Group said it completed pricing negotiations with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) for Teysuno tegafur/gimeracil/oteracil to treat advanced gastric cancer in combination with cisplatin. Nordic said the price it negotiated with GKV-Spitzenverband for 42 capsules of the 15/4.35/11.8 mg strength is €177.39 ($236.46) and €232.87 ($310.42) for the 20/5.8/15.8 mg strength. Nordic launched the drug last year with a price of €195.41 ($260.48) for the low strength and €257.04 ($342.63) for the higher strength. ...